# Oral Hypoglycaemics

|Class|Biguanides|Sulfonylureas|Glitazones
|--|--|
|**Example**|Metformin|Gliclazide|Pioglitazone|
|**Uses**|T2DM|T2DM|T2DM|
|**Mechanism of Action**|Delay glucose absorption, increase peripheral insulin sensitivity, inhibit hepatic gluconeogenesis|Increase insulin secretion from pancreatic β-cells. May increase insulin sensitivity|Activates the intranucleic PPARγ receptor, affecting gene translation and increasing insulin sensitivity
|**Dosing**|500mg-2g BD|40-160mg BD|15-30mg daily|
|**Absorption**|Bioavailability 60%|Bioavailability 80%|High bioavailability. Delayed onset and late peak effect given MoA|
|**Distribution**|Minimally protein bound|Extensively bound to albumin by non-ionic forces, such that they do not tend to displace other highly protein bound drugs|Low V<sub>D</sub> (0.6L.kg<sup>-1</sup>)
|**Metabolism**|Not metabolised|Partial hepatic to inactive metabolites|Extensive hepatic phase I to inactive and active metabolites
|**Elimination**|Renal elimination of active drug|Renal elimination of active drug and inactive metabolites|Renal and GI elimination of active and inactive metabolites|
|**CVS**|||May precipitate fluid retention
|**Metabolic**|Severe lactic acidosis, especially in renal failure and alcoholics|↑ appetite, weight gain||
|**GIT**|Diarrhoea||||

---
##References
Peck and Hill